The summary below was generated by an AI language model and may contain errors or omissions. All other content on this page is deterministically extracted from the original SEC EDGAR filing.
Merck removed three geopolitical and pandemic-related risk disclosures from its 2024 10-K, reflecting a shift away from acute external disruptions that dominated 2023 risk narratives. The company substantially modified eight risks, with particular emphasis on cybersecurity threats, pricing pressures, and ESG concerns, indicating these have become material strategic focuses. No new risks were introduced, suggesting Merck's risk landscape remained relatively stable year-over-year while existing operational and market risks received enhanced disclosure treatment.
Classification is based on semantic text similarity scoring and may include approximations. “No match” means no high-confidence textual match was found — not necessarily that a section was removed.
🔴 No Match in Current Filing
The Company faces intense competition from competitors’ products.
🔒
🔴 No Match in Current Filing
COVID-19-related disruptions have had an adverse impact on the Company’s business, operations and financial performance. The Company is unable to predict the full extent to which the COVID-19 pandemic or any future pandemic, epidemic or similar public health threat will adversely impact its business, operations, financial performance, results of operations, and financial condition.
🔒
🔴 No Match in Current Filing
The ongoing war between Russia and Ukraine and related global disruptions could adversely affect the Company’s business, results of operations and financial condition.
🔒
🟡 Modified
The Company is increasingly dependent on sophisticated software applications and computing infrastructure. The Company continues to be a target of cyber-attacks that could lead to a disruption of its worldwide operations, including manufacturing, research and sales operations.
🔒
🟡 Modified
The Company faces continued pricing pressure with respect to its products.
🔒
🟡 Modified
Environmental, social and governance (ESG) matters may impact the Company’s business and reputation.
🔒
🟡 Modified
The Company is exposed to market risk from fluctuations in currency exchange rates and interest rates.
🔒
🟡 Modified
Adverse outcomes in current or future legal matters could negatively affect Merck’s business.
🔒
🟡 Modified
The Company faces intense competition from both lower cost generic products and competitors’ products.
🔒
🟡 Modified
Key products generate a significant amount of the Company’s profits and cash flows, and any events that adversely affect the markets for its leading products could have a material adverse effect on the Company’s results of operations and financial condition.
🔒
🟡 Modified
As the Company’s products lose market exclusivity, the Company generally experiences a significant and rapid loss of sales from those products.
🔒